Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Bluecat Solutions GmbH is currently navigating 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This prosecution involves a distinct examiner and is located in 1 distinct art unit. The concentration of the portfolio into a single art unit suggests a technical focus for the pending application. In the field of Biotechnology & Pharmaceuticals, such focus often implies that the patent office is evaluating a biological or chemical matter rather than a diverse array of technologies.
The busiest examiner for this entity is CLARKE, TRENT R, who is handling a pending office action. Given that there is only a single distinct examiner and a single distinct art unit, the prosecution process is entirely centralized. This means the company's current interaction with the patent office is limited to a single examiner's review within one specialized technical group. This centralization allows for a targeted prosecution strategy, as the applicant only needs to address the requirements of the individual reviewer at this stage.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CLARKE, TRENT R | 1 | 42.2% | +24.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18718814 | Reaction vessel unit, method for selectively removing a liquid and for introducing a liquid containing a target substance from or into a reaction vessel of a reaction vessel unit | CLARKE, TRENT R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18718814 | Reaction vessel unit, method for selectively removing a liquid and for introducing a liquid containing a target substance from or into a reaction vessel of a reaction vessel unit | CLARKE, TRENT R | — |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18718814 | Reaction vessel unit, method for selectively removing a liquid and for introducing a liquid containing a target substance from or into a reaction vessel of a reaction vessel unit | CLARKE, TRENT R | 1651 | §102§103§112 | Non-Final OA | — | Pending | Jun 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBluecat Solutions GmbH has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Trent R Clarke has the most, with 1 of Bluecat Solutions GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
